Panitumumab in RAS Wild-Type Left-Sided mCRC: Evidence Synthesis
This narrative review consolidates the biomarker-driven positioning of panitumumab and emerging combination strategies for oncology pharmacists managing metastatic colorectal cancer.
📅 Journal publication: Aug 24, 2026·Last updated: Sep 23, 2026
Panitumumab extends survival in metastatic colorectal cancer with precision therapy advances.
Metastatic colorectal cancer (mCRC) is a leading cause of cancer-related deaths, and targeted therapies like panitumumab offer potential improvements in treatment outcomes. Panitumumab extends overall survival by 5.6 months in first-line treatment. ctDNA analysis predicts treatment eligibility with a 30% response rate observed in rechallenge cases. Panitumumab shows significant efficacy in RAS wild-type mCRC, especially in left-sided tumors. Advances in molecular stratification and ctDNA monitoring can optimize its use. Panitumumab is vital for RAS wild-type mCRC treatment, with precision strategies enhancing its deployment.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Kwiatkowska L, Szczuko M
Citation:Kwiatkowska L, Szczuko M The Role of Monoclonal Antibody Targeted Therapy (Panitumumab) in the Treatment of Metastatic Colorectal Cancer-A Narrative Review of Current Evidence and Emerging Therapeutic Strategies. International journal of molecular sciences. 2026;27(17). doi:10.3390/ijms27177559